Product Images Venlafaxine Hydrochloride

This is a medication description for #30 E-R Capsules Venlafaxine HCI 75mg. It includes details such as LOT number, manufacturer's NDC, and expiration date. Additionally, there is a warning to keep the medication out of the reach of children and to store it at a controlled temperature of 68-77°F. The label also recommends seeking medical advice from a doctor and provides a contact number to report side effects to the FDA.*

This is a drug interaction chart showing the effects of ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium on the CYP2D6 EM's and PM's in the body. The chart also provides information on the effects of venlafaxine on the body's PK Fold Change and 90% C recommendations in terms of Cmax and AUC. The chart provides recommendations on how to use these drugs safely and effectively, including avoiding concurrent use, using with caution in certain patients, monitoring blood pressure, and making no dose adjustments.*

This appears to be a chart displaying drug interactions and their effects on analytes. The table lists various drugs and their interactions with other drugs or substances such as caffeine and ethanol. It also indicates the potential impact on different active moieties, and notes whether or not dosage adjustments should be made as well as any unknown clinical significance.*

This is a report containing recommendations for dosage adjustments of the drug Venlafaxine based on factors such as hepatic impairment, renal impairment, age, gender, and genetic polymorphism. The fold change and 90% CI are also included in the report. Dosage reduction is recommended for most special populations, except for individuals with CYP2D8 polymorphism and with no hepatic or renal impairment.*

eHCI and H4C0 C are not recognizable as meaningful text. The second line appears to be a chemical formula or drug name for "venlafaxine hydrochloride".*